Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Diabetes Care · 2023
DOI: 10.2337/dc23-0492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2023. Verfasst von Filipe A Moura und 12 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Myocardial Infarction, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NHLBI NIH HHS, Brigham and Women’s Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To develop a risk assessment tool to identify patients with type 2 diabetes (T2D) at higher risk for kidney disease progression and who might benefit more from sodium–glucose cotransporter 2 (SGLT2) inhibition. RESEARCH DESIGN AND METHODS A total of 41,204 patients with T2D from four Thrombolysis In Myocardial Infarction (TIMI) clinical trials were divided into derivation (70%) and validation cohorts (30%). Candidate predictors of kidney disease progression (composite of sustained ≥40% decline in estimated glomerular filtration rate [eGFR], end-stage kidney disease, or kidney death) were selected with multivariable Cox regression. Efficacy of dapagliflozin was assessed by risk categories (low: <0.5%; intermediate: 0.5 to <2%; high: ≥2%) in Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58. RESULTS There were 695 events over a median follow-up of 2.4 years. The final model comprised eight independent predictors of kidney disease progression: atherosclerotic cardiovascular disease, heart failure, systolic blood pressure, T2D duration, glycated hemoglobin, eGFR, urine albumin-to-creatinine ratio, and hemoglobin. The c-indices were 0.798 (95% CI, 0.774–0.821) and 0.798 (95% CI, 0.765–0.831) in the derivation and validation cohort, respectively. The calibration plot slope (deciles of predicted vs. observed risk) was 0.98 (95% CI, 0.93–1.04) in the validation cohort. Whereas relative risk reductions with dapagliflozin did not differ across risk categories, there was greater absolute risk reduction in patients with higher baseline risk, with a 3.5% absolute risk reduction in kidney disease progression at 4 years in the highest risk group (≥1%/year). Results were similar with the 2022 Chronic Kidney Disease Prognosis Consortium risk prediction model. CONCLUSIONS Risk models for kidney disease progression can be applied in patients with T2D to stratify risk and identify those who experience a greater magnitude of benefit from SGLT2 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- Division of Nephrology and Hypertension, University of Utah Health, Salt Lake City, UT.
- Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY.
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
ORCID-Profile: Filipe A Moura, David D Berg, Ofri Mosenzon, Benjamin M Scirica, Marc S Sabatine
Förderung
- American Heart Association-American Stroke Association
- NHLBI NIH HHS
- Brigham and Women’s Hospital
- American Heart Association
Zitieren
APA
Moura, F. A., Berg, D. D., Bellavia, A., Dwyer, J. P., Mosenzon, O., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Raz, I., Feinberg, M. W., Braunwald, E., Morrow, D. A., & Sabatine, M. S. (2023). Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc23-0492
Vancouver
Moura FA, Berg DD, Bellavia A, Dwyer JP, Mosenzon O, Scirica BM, et al. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. 2023. doi:10.2337/dc23-0492
BibTeX
@article{Moura2023,
author = {Moura, Filipe A and Berg, David D and Bellavia, Andrea and Dwyer, Jamie P and Mosenzon, Ofri and Scirica, Benjamin M and Wiviott, Stephen D and Bhatt, Deepak L and Raz, Itamar and Feinberg, Mark W and Braunwald, Eugene and Morrow, David A and Sabatine, Marc S},
title = {Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes},
journal = {Diabetes Care},
year = {2023},
doi = {10.2337/dc23-0492}
}
EUVIMED